China's promise of an accelerated approval pathway for a list of 48 drugs approved elsewhere to treat life-threatening or rare diseases could be a good opportunity for the companies that make the drugs, but once again the devil will be in the details, Hogan Lovells partner Philip Katz told BioWorld.